Factor Xa
Fxa
Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.
Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.
All Product Categories
-
Factor Xa Related Products (166)
Related Products (166)
-
Antibodies (1)
-
Rabbit Factor Xa
0 ImagesPorcine Factor Xa is a serine protease that plays a central role in blood coagulation, with prothrombin as its physiological substrate. Porcine Factor Xa catalyzes the conversion of prothrombin to thrombin, activates factor VIII, and hydrolyzes peptide, thioester, and amide substrates. Porcine Factor Xa cleaves protease-activated receptors 1 and 2 to activate intracellular signal transduction. Porcine Factor Xa regulates multiple cellular pathways, mediates various cellular activities, tissue remodeling and cancer cell migration, and inhibits apoptosis in some cancer cells. Porcine Factor Xa protects hippocampal neurons against glutamate-induced damage. Porcine Factor Xa participates in embryonic vascular development and regulates immune hematopoiesis; its activity is inhibited by soybean trypsin inhibitor, and cannot be enhanced by phospholipids. Porcine Factor Xa regulates immune responses and macrophage polarization, and participates in fibrosis, vascular remodeling and tumor progression through non-coagulant effects. Porcine Factor Xa can be used in research related to atherosclerosis, fibrosis, asthma, cancer, thromboinflammation, sepsis, etc.
-
BMS-269223
0 ImagesCat. No.: HY-10778CAS No.: 288077-60-1BMS-269223 is a potent, selective and orally active factor Xa inhibitor (Ki = 6.5 nM, EC2xPT = 32 μM). BMS-269223 can prolong prothrombin time and inhibit thrombosis formation. BMS-269223 can be used for the research of cardiovascular disease.
-
BMS-344577
0 ImagesCat. No.: HY-10779CAS No.: 288079-93-6BMS-344577 (Compound 22) is a potent and orally active factor Xa inhibitor (IC50 = 4 nM, EC2xPT = 7 μM). BMS-344577 shows potent CYP3A4 inhibition activity (IC50 = 0.3 μM). BMS-344577 can be used for the research of cardiovascular disease.
-
DX-9065a free base
0 ImagesCat. No.: HY-10722ACAS No.: 150612-55-8DX-9065a free base is a selective, nonpeptidic, and orally active factor Xa (FXa) inhibitor with a Ki of 41 nM for human FXa. DX-9065a free base has low activity against other serine proteases. DX-9065a free base has strong anticoagulant actions.
-
FXIa-IN-9
0 ImagesCat. No.: HY-150682CAS No.: 2816108-87-7FXIa-IN-9 (compound 3f) is a potent and selective FXIa inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa Ki: 0.17 nM, rabbit FXIa Ki: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism.
-
DPC423 free base
0 ImagesCat. No.: HY-11090CAS No.: 209957-47-1DPC423 free base is a selective and orally active factor Xa inhibitor with a Kis of 0.15 (human) and 0.3 (rabbit) nM. DPC423 free base exhibits Kis of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 free base blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 free base can be used for the study of anticoagulation of arterial thrombosis.
-
ChloraMine-T hydrate
0 ImagesSynonyms: Sodium chloro(4-methylbenzenesulfonyl)azanide hydrateChloraMine-T hydrate (Sodium chloro(4-methylbenzenesulfonyl)azanide (hydrate)) is a common reagent in various synthetic processes. It has been used as a reagent in aminohydroxylation and allylic amination reactions, a nitrogen source in aziridination reactions of alkenes and alkenes, and deprotection of sulfur groups in sulfur-containing compounds. It has been used as a reagent in the synthesis of factor Xa inhibitors. ChloraMine-T hydrate (Sodium chloro(4-methylbenzenesulfonyl)azanide (hydrate)) (0.2% w/v) is also an antimicrobial agent that kills Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Proteus mirabilis, and Enterococcus cloacae.
-
Delparantag
0 ImagesCat. No.: HY-105240CAS No.: 872454-31-4Synonyms: PMX-60056Delparantag (PMX-60056) is a salicylamide derivative and an effective unfractionated heparin (UFH) and low molecular weight heparin (LMWH) reversing agent. Delparantag shows ability to neutralize the anticoagulation and bleeding effects of UFH and LMWH.
-
Anivamersen sodium
0 ImagesCat. No.: HY-153836ACAS No.: 959716-31-5Anivamersen sodium is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
-
Ciraparantag-d8 tetrahydrochloride diacetate
0 ImagesCat. No.: HY-18660SSynonyms: PER977-d8 tetrahydrochloride diacetateCiraparantag-d8 (PER977-d8) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
-
Heparin pentasaccharide
0 ImagesCat. No.: HY-W854549CAS No.: 104993-28-4Synonyms: Fondaparinux free acidHeparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events.
-
Otamixaban hydrochloride
0 ImagesCat. No.: HY-76409CAS No.: 409081-12-5Synonyms: FXV673 hydrochlorideOtamixaban (FXV673) is a potent, selective, rapid-acting, competitive, and reversible fXa inhibitor (Ki=0.5 nM) that effectively inhibits both free and prothrombinase-bound fXa.
-
L-Guluronic acid
0 ImagesL-Guluronic acid is a coagulation factor X inhibitor. L-Guluronic acid can replace L-Iduronic acid (HY-135197) in the anticoagulant pentasaccharide of heparin-like substances, while retaining the inhibitory activity against factor Xa. L-Guluronic acid can be used in the research of diseases with coagulation disorders such as deep vein thrombosis and pulmonary embolism.
-
Bz-Pro-Phe-Arg-pNA hydrochloride
0 ImagesSynonyms: Bz-PFR-pNA hydrochlorideBz-Pro-Phe-Arg-pNA (Bz-PFR-pNA) hydrochloride is a chromogenic peptide substrate for plasma and glandular Kallikrein, cysteine proteinase (Cruzipain) and Trypsin. Bz-Pro-Phe-Arg-pNA hydrochloride can be used in Factor XII assay.
-
Neutrophil elastase-IN-7
0 ImagesNeutrophil elastase-IN-7 is a human neutrophil elastase inhibitor with an IC50 of 0.54 μM. Neutrophil elastase-IN-7 also exhibits significant inhibitory activity against multiple coagulation proteins, with IC50 values of 8.2, 12.7, 1.2 and 5.7 μM against thrombin, FXa, FXIa and FXIIIa, respectively. Neutrophil elastase-IN-7 can be used in the research of cardiopulmonary diseases and inflammatory diseases.
-
Milvexian TFA
0 ImagesCat. No.: HY-125856ACAS No.: 1802426-00-1Synonyms: BMS-986177 TFA; JNJ-70033093 TFAMilvexian TFA (BMS-986177 TFA) is a factor XIa inhibitor with biological activity to prevent venous thromboembolism. Milvexian TFA was effective in reducing the occurrence of venous thromboembolism in patients undergoing knee replacement surgery. Milvexian TFA has good selectivity and shows significant inhibitory effects on plasma kallikrein and trypsin. Milvexian TFA has a bioavailability of 32%, which means it has a high absorption rate in the body. Milvexian TFA showed a relatively low risk of bleeding in clinical trials.
-
BMS-654457
0 ImagesCat. No.: HY-12631CAS No.: 1004551-41-0BMS-654457 is a small-molecule, reversible inhibitor of factor XIa (FXIa), binding with human and rabbit FXIa with Kis of 0.2 and 0.42 nM, respectively.
-
FXIa-IN-8
0 ImagesCat. No.: HY-144658CAS No.: 2744293-04-5FXIa-IN-8 is a potent and selective FXIa inhibitor with an IC50 of 14.2 nM. FXIa-IN-8 shows antithrombotic activity without increasing the bleeding risk and obvious toxicitysup>[1].
-
ARC19499 sodium scrambled negative control
0 ImagesCat. No.: HY-153480CARC19499 sodium scrambled negative control is the sequence scrambled negative control of ARC19499 sodium.
